Senior biopharmaceutical executive with a proven track record of delivering outstanding business results in the U.S. and internationally; strategically positioning and advancing pipeline products for successful launches; and building winning teams and alliances: - Consistently achieved or exceeded P&L targets, boosting revenues and profit growth; - Science-based marketer with deep leadership experience in advancing new molecules through the drug development process; - Broad strategic and operational expertise acquired by building and leading businesses in the U.S. and internationally; - Successfully launched and commercialized products in oncology, immunology, bone health, neuroscience, cardiology, gastroenterology, nephrology and dermatology; - Effectively led cross-functional initiatives and strategic alliances.

SVP & Chief Marketing Officer @ Alexion is a fast growing, global biopharmaceutical company that applies groundbreaking science to serving the needs of patients suffering from severe, ultra-rare diseases. Member of the Executive Committee. Reports to the CEO. Accountable for Alexion's commercial operations and P&L in the US and Latin America ($877M in 2014 revenues). Leads the growth of Alexion's global therapeutic franchises including SOLIRIS (eculizumab) in paroxysmal noctunal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) as well as the worldwide launch of asfotase alpha, a first-in-class enzyme replacement therapy for hypophosphatasia. Also responsible for New Products Planning, Global Business Operations and the commercial evaluation of outreach opportunities. From May 2014 to Present (1 year 8 months) Managing Director @ Senior consultant to the biotech and pharmaceutical industry with extensive leadership experience in P&L management, strategic marketing, global brand management, sales effectiveness and access and reimbursement in the U.S. and Europe. Advisor to DRI Capital, a leading private equity firm seeking global investment opportunities for a newly raised $1.45B life-science fund. From August 2013 to May 2014 (10 months) VP General Manager Inflammation Business Unit @ Accountable for $4B P&L. Turned around the competitive performance of ENBREL, Amgen's largest brand and the leading biologic in rheumatology and dermatology sales, and returned it to double-digit growth. Accelerated the transition out of the co-promotion with Pfizer. From August 2011 to July 2013 (2 years) VP & Head, Global Marketing & Commercial Development @ Led the marketing strategies for Amgen's industry-leading pipeline across therapeutic areas (oncology, inflammation, bone health, cardiology, neuroscience and nephrology). Led the global launch of denosumab, Amgen's leading growth driver, in osteoporosis (PROLIA) and oncology (XGEVA). Responsible for the commercial organization's engagement in business development activities. Chaired the Global Commercial Committee. President of the Kirin-Amgen partnership. From November 2007 to July 2011 (3 years 9 months) VP Global Commercial Development @ Created the Global Commercial Development function to lead the commercial assessment of in-licensing and business development opportunities. Chaired Amgen's Global Biosimilar Task Force. Led Amgen's commercial strategy in Japan. From January 2007 to November 2007 (11 months) VP, International Marketing & Business Operations @ Built Amgen's international commercial capability and led the creation of Amgen's international franchises in oncology and nephrology. Shared accountability for growing Amgen's international revenues seven-fold to $2.2B. From July 2002 to December 2006 (4 years 6 months) Head, CV/CNS & Allergy Business Units - Global Marketing @ Co-led the collaboration with Merck & Co. for the development and strategic positioning of ezetimibe in the international lipid lowering market. Responsible for S-P's $450M global allergy franchise; provided strategic leadership for the successful launch of desloratadine (Aerius, NeoClarityn) internationally. From January 2001 to June 2002 (1 year 6 months) General Manager @ Full P&L accountability. Grew sales by >15% annually, establishing S-P as one of the fastest growing companies in the UK. Launched Remicade in Crohn's disease and RA; the bi-therapy of ribavirin and interferon in Hep C; Temodal in brain cancer; Subutex in opiate addiction. Responsible for 540 staff. Member of the ABPI Board of Management. From July 1998 to December 2000 (2 years 6 months) Director, Primary Care Business Unit @ From January 1997 to June 1998 (1 year 6 months) Manager, Primary Care Business Unit @ From January 1995 to December 1996 (2 years)

MBA @ INSEAD From 1986 to 1987 Dominique Monnet is skilled in: Global Marketing, Management, Cross-functional Team Leadership, Market Analysis, Biotechnology, Product Development, Commercialization, Market Development, Strategy, Competitive Analysis, Cardiology, Sales Effectiveness, Oncology, Gastroenterology, Pharmaceutical Industry, Biopharmaceuticals, Life Sciences